BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19016040)

  • 1. Urethral dose and increment of international prostate symptom score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer.
    Murakami N; Itami J; Okuma K; Marino H; Nakagawa K; Ban T; Nakazato M; Kanai K; Naoi K; Fuse M
    Strahlenther Onkol; 2008 Oct; 184(10):515-9. PubMed ID: 19016040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
    Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
    Allen ZA; Merrick GS; Butler WM; Wallner KE; Kurko B; Anderson RL; Murray BC; Galbreath RW
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):981-7. PubMed ID: 15989998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
    Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy.
    Thomas C; Keyes M; Liu M; Moravan V
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):447-55. PubMed ID: 18395357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary symptom flare following I-125 prostate brachytherapy.
    Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial changes of international prostate symptom score following I-125 prostate brachytherapy.
    Ohashi T; Yorozu A; Toya K; Saito S; Momma T
    Int J Clin Oncol; 2006 Aug; 11(4):320-5. PubMed ID: 16937307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dosimetry of prostate brachytherapy-induced urethral strictures.
    Merrick GS; Butler WM; Tollenaar BG; Galbreath RW; Lief JH
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):461-8. PubMed ID: 11872293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predicting for urinary incontinence after prostate brachytherapy.
    McElveen TL; Waterman FM; Kim H; Dicker AP
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Allen ZA; Lief JH; Hinerman-Mulroy A; Galbreath RW
    Cancer J; 2004; 10(3):181-9. PubMed ID: 15285928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between prostate brachytherapy-related urethral stricture and peri-apical urethral dosimetry: a matched case-control study.
    Earley JJ; Abdelbaky AM; Cunningham MJ; Chadwick E; Langley SE; Laing RW
    Radiother Oncol; 2012 Aug; 104(2):187-91. PubMed ID: 22841018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
    Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
    Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postimplantation dosimetric analysis of permanent transperineal prostate implantation: improved dose distributions with an intraoperative computer-optimized conformal planning technique.
    Zelefsky MJ; Yamada Y; Cohen G; Venkatraman ES; Fung AY; Furhang E; Silvern D; Zaider M
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):601-8. PubMed ID: 10974481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy.
    Ferro A; Bae HJ; Yenokyan G; Le Y; McNutt T; Mian O; Gergis C; Haviland C; DeWeese TL; Song DY
    Brachytherapy; 2018; 17(2):313-318. PubMed ID: 29174937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
    J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.
    Zelefsky MJ; Hollister T; Raben A; Matthews S; Wallner KE
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1261-6. PubMed ID: 10889379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.